[go: up one dir, main page]

MX2018007681A - An oral osmotic pharmaceutical composition of vildagliptin. - Google Patents

An oral osmotic pharmaceutical composition of vildagliptin.

Info

Publication number
MX2018007681A
MX2018007681A MX2018007681A MX2018007681A MX2018007681A MX 2018007681 A MX2018007681 A MX 2018007681A MX 2018007681 A MX2018007681 A MX 2018007681A MX 2018007681 A MX2018007681 A MX 2018007681A MX 2018007681 A MX2018007681 A MX 2018007681A
Authority
MX
Mexico
Prior art keywords
vildagliptin
pharmaceutical composition
salt
surrounding
osmotic pharmaceutical
Prior art date
Application number
MX2018007681A
Other languages
Spanish (es)
Inventor
Madhukar Kodgule Mandar
Bansal Amit
Sangle Ganesh
Swain Kapileshwar
Saigal Nitin
Gaikwad Sanjay
Kumar Agarwal Sunil
Original Assignee
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Ltd filed Critical Wockhardt Ltd
Publication of MX2018007681A publication Critical patent/MX2018007681A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

There is provided an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1:1 to about 1:5; (b) a seal coat surrounding the core; (c) a sustained release coat cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising vildagliptin or salt thereof surrounding the sustained release coat. Also provided is process of preparing such compositions.
MX2018007681A 2015-12-28 2016-12-23 An oral osmotic pharmaceutical composition of vildagliptin. MX2018007681A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN4891MU2015 2015-12-28
PCT/IB2016/057975 WO2017115252A1 (en) 2015-12-28 2016-12-23 An oral osmotic pharmaceutical composition of vildagliptin

Publications (1)

Publication Number Publication Date
MX2018007681A true MX2018007681A (en) 2018-11-14

Family

ID=57966046

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007681A MX2018007681A (en) 2015-12-28 2016-12-23 An oral osmotic pharmaceutical composition of vildagliptin.

Country Status (6)

Country Link
KR (1) KR20180092981A (en)
BR (1) BR112018013195A2 (en)
MX (1) MX2018007681A (en)
PH (1) PH12018550075A1 (en)
RU (1) RU2706706C1 (en)
WO (1) WO2017115252A1 (en)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122010000020I1 (en) 1996-04-25 2010-07-08 Prosidion Ltd Method for lowering the blood glucose level in mammals
CO5150173A1 (en) 1998-12-10 2002-04-29 Novartis Ag COMPOUNDS N- (REPLACED GLYCLE) -2-DIPEPTIDYL-IV PEPTIDASE INHIBITING CYANOPIRROLIDINS (DPP-IV) WHICH ARE EFFECTIVE IN THE TREATMENT OF CONDITIONS MEDIATED BY DPP-IV INHIBITION
EP1537880A4 (en) 2002-09-11 2009-07-01 Takeda Pharmaceutical PREPARATION FOR PROLONGED RELEASE
MY152185A (en) * 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
AU2006292377B2 (en) 2005-09-20 2011-03-03 Emisphere Technologies, Inc. Use of a DPP-IV inhibitor to reduce hypoglycemic events
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
US20100323011A1 (en) * 2008-03-04 2010-12-23 Nazaneen Pourkavoos Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
ES2487271T3 (en) 2011-10-06 2014-08-20 Sanovel Ilac Sanayi Ve Ticaret A.S. DPP-IV inhibitor solid dosage formulations
AU2013304942A1 (en) 2012-08-23 2015-03-05 Cardiolynx Ag Extended release compositions of an aminoalkyl nitrate

Also Published As

Publication number Publication date
BR112018013195A2 (en) 2018-12-11
PH12018550075A1 (en) 2019-01-28
WO2017115252A1 (en) 2017-07-06
KR20180092981A (en) 2018-08-20
RU2706706C1 (en) 2019-11-20

Similar Documents

Publication Publication Date Title
WO2015184127A3 (en) Stable cannabinoid formulations
AU2018231044A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
CL2016002560A1 (en) Oral solid pharmaceutical dosage form comprising siponimod, a moisture protective agent and optionally a pharmaceutical excipient; Preparation procedure
PH12017502376B1 (en) Oral solid formulation containing irinotecan and method of preparing the same
EP3590498A4 (en) Preparation, comprising inclusion complex of varenicline or pharmaceutically acceptable salt thereof, for oral administration
ECSP16084317A (en) PHARMACEUTICAL FORMULATIONS, PREPARATION PROCESSES AND METHODS OF USE
WO2020127819A3 (en) Pharmaceutical composition comprising apixaban
WO2019194773A3 (en) The combination comprising linagliptin and metformin
WO2019203771A3 (en) Solid oral pharmaceutical compositions comprising sitagliptin
WO2015125152A3 (en) Pharmaceutical compositions of asenapine
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
PH12016500693A1 (en) Slow-release solid oral compositions
EP3648745A4 (en) Pharmaceutical composition including multi-unit spheroidal tablet containing esomeprazole and spheroidal pharmaceutically acceptable salt thereof, and method of preparing the pharmaceutical composition
EA201991286A1 (en) A SOLID PHARMACEUTICAL COMPOSITION FOR ORAL USE CONTAINING TENOFOVIR AND EMTRITSITABIN
MX2021014830A (en) CONJUGATES OF <i>π</i>-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS.
CY1125762T1 (en) NEW BY THE MOUTH PREPARATION VELINOSTATIS
WO2017064652A3 (en) Low dose oral dipyridamole compositions and uses thereof
PH12018550075A1 (en) An oral osmotic pharmaceutical composition of vildagliptin
WO2016167605A3 (en) Method for inhibiting lung cancer of smokers and non-smokers using hypertension medicine
WO2018069805A3 (en) Method for preparation of liquid oral composition of l-thyroxin
WO2016108507A3 (en) Composite tablet for oral administration comprising melatonin and sertraline
WO2020018053A3 (en) The tablet comprising dasatinib
WO2016187595A3 (en) Oral pharmaceutical composition of methylergonovine
PH12016502527B1 (en) Stabilized desmopressin
WO2013054178A8 (en) Extended release pharmaceutical compositions containing carmabazepine